Skip to main content
Erschienen in: MMW - Fortschritte der Medizin 4/2017

06.03.2017 | Prostatakarzinom | FORTBILDUNG . ÜBERSICHT

Update 2017

Das müssen Sie heute zum Prostatakarzinom wissen

verfasst von: Dr. med. Annika Herlemann, Dr. med. Alexander Kretschmer, Maria Apfelbeck, PD Dr. med. Stefan Tritschler, Dr. med. Wolfgang Fendler, Prof. Dr. med. Peter Bartenstein, Prof. Dr. med. Dr. h.c. Maximilian Reiser, Prof. Dr. med. Christian G. Stief, Prof. Dr. med. Christian Gratzke

Erschienen in: MMW - Fortschritte der Medizin | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Was soll in der Frühdiagnostik des Prostatakarzinoms unternommen werden? Haben Screeningmaßnahmen einen Nutzen? Welchen Stellenwert hat die Bestimmung des Prostata-spezifischen Antigens? Welche Empfehlungen zur Therapie gibt es? Wie sind die Erfolgsaussichten? Die Antworten auf diese Fragen finden Sie in diesem Beitrag.
Literatur
2.
Zurück zum Zitat Hoedemaeker RF et al. Histopathological prostate cancer characteristics at radical prostatectomy after population based screening. J Urol. 2000;164:411–5CrossRefPubMed Hoedemaeker RF et al. Histopathological prostate cancer characteristics at radical prostatectomy after population based screening. J Urol. 2000;164:411–5CrossRefPubMed
3.
Zurück zum Zitat Mottet N et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2016. Mottet N et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2016.
5.
Zurück zum Zitat Roobol MJ et al. Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer. Eur Urol. 2013;64:530–9CrossRefPubMed Roobol MJ et al. Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer. Eur Urol. 2013;64:530–9CrossRefPubMed
6.
Zurück zum Zitat Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120–33CrossRefPubMed Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120–33CrossRefPubMed
7.
Zurück zum Zitat Weiner AB et al. Increasing incidence of metastatic prostate cancer in the United States (2004–2013). Prostate Cancer Prostatic Dis. 2016 Weiner AB et al. Increasing incidence of metastatic prostate cancer in the United States (2004–2013). Prostate Cancer Prostatic Dis. 2016
9.
Zurück zum Zitat Herlemann A, Stief CG. Active surveillance for low-risk prostate cancer. Urologe A. 2016;55:269–81CrossRefPubMed Herlemann A, Stief CG. Active surveillance for low-risk prostate cancer. Urologe A. 2016;55:269–81CrossRefPubMed
10.
11.
Zurück zum Zitat van der Poel H, Klotz L, Stief CG. Management of low- and intermediate-risk prostate cancer. World J Urol. 2015;33:905–6CrossRefPubMed van der Poel H, Klotz L, Stief CG. Management of low- and intermediate-risk prostate cancer. World J Urol. 2015;33:905–6CrossRefPubMed
12.
Zurück zum Zitat van der Poel H et al. Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers. World J Urol. 2015;33:907–16CrossRefPubMed van der Poel H et al. Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers. World J Urol. 2015;33:907–16CrossRefPubMed
13.
Zurück zum Zitat Dinh KT et al. Incidence and Predictors of Upgrading and Up Staging among 10.000 Contemporary Patients with Low Risk Prostate Cancer. J Urol. 2015;194:343–9CrossRefPubMed Dinh KT et al. Incidence and Predictors of Upgrading and Up Staging among 10.000 Contemporary Patients with Low Risk Prostate Cancer. J Urol. 2015;194:343–9CrossRefPubMed
14.
Zurück zum Zitat Lellig E et al. Final pathohistology after radical prostatectomy in patients eligible for active surveillance (AS). World J Urol. 2015;33: 917–22CrossRefPubMed Lellig E et al. Final pathohistology after radical prostatectomy in patients eligible for active surveillance (AS). World J Urol. 2015;33: 917–22CrossRefPubMed
15.
Zurück zum Zitat de Rooij M et al. Accuracy of Magnetic Resonance Imaging for Local Staging of Prostate Cancer: A Diagnostic Meta-analysis. European Urology. 2015 de Rooij M et al. Accuracy of Magnetic Resonance Imaging for Local Staging of Prostate Cancer: A Diagnostic Meta-analysis. European Urology. 2015
16.
Zurück zum Zitat Futterer JJ et al. Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. European Urology. 2015;68:1045–53CrossRefPubMed Futterer JJ et al. Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. European Urology. 2015;68:1045–53CrossRefPubMed
17.
Zurück zum Zitat Otto J et al. Value of endorectal magnetic resonance imaging at 3T for the local staging of prostate cancer. Rofo. 2014;186:795–802CrossRefPubMed Otto J et al. Value of endorectal magnetic resonance imaging at 3T for the local staging of prostate cancer. Rofo. 2014;186:795–802CrossRefPubMed
18.
Zurück zum Zitat Ruprecht O et al. MRI of the prostate: interobserver agreement compared with histopathologic outcome after radical prostatectomy. Eur J Radiol. 2012;81:456–60CrossRefPubMed Ruprecht O et al. MRI of the prostate: interobserver agreement compared with histopathologic outcome after radical prostatectomy. Eur J Radiol. 2012;81:456–60CrossRefPubMed
19.
Zurück zum Zitat Billing A et al. Preoperative mp-MRI of the prostate provides little information about staging of prostate carcinoma in daily clinical practice. World J Urol. 2015;33:923–8CrossRefPubMed Billing A et al. Preoperative mp-MRI of the prostate provides little information about staging of prostate carcinoma in daily clinical practice. World J Urol. 2015;33:923–8CrossRefPubMed
20.
21.
Zurück zum Zitat Azzouzi AR et al. TOOKAD(R) Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer. World J Urol 2015;33:945–53CrossRefPubMedPubMedCentral Azzouzi AR et al. TOOKAD(R) Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer. World J Urol 2015;33:945–53CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Siddiqui MM et al. Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol. 2013;64:713–9CrossRefPubMed Siddiqui MM et al. Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol. 2013;64:713–9CrossRefPubMed
23.
Zurück zum Zitat Meiers I, Waters DJ, Bostwick DG. Preoperative prediction of multifocal prostate cancer and application of focal therapy: review 2007. Urology. 2007;70(6 Suppl):3–8CrossRefPubMed Meiers I, Waters DJ, Bostwick DG. Preoperative prediction of multifocal prostate cancer and application of focal therapy: review 2007. Urology. 2007;70(6 Suppl):3–8CrossRefPubMed
26.
Zurück zum Zitat Tritschler S, Ganswindt U, Stief CG. Localized intermediate- to high-risk prostate cancer. Urologe A. 2016;55:318–25CrossRefPubMed Tritschler S, Ganswindt U, Stief CG. Localized intermediate- to high-risk prostate cancer. Urologe A. 2016;55:318–25CrossRefPubMed
27.
Zurück zum Zitat Hamdy FC et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med. 2016 Hamdy FC et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med. 2016
28.
Zurück zum Zitat Donovan JL et al. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med. 2016. Donovan JL et al. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med. 2016.
30.
Zurück zum Zitat Wilt TJ et al. Association between hospital and surgeon radical prostatectomy volume and patient outcomes: a systematic review. J Urol. 2008;180:820–9CrossRefPubMed Wilt TJ et al. Association between hospital and surgeon radical prostatectomy volume and patient outcomes: a systematic review. J Urol. 2008;180:820–9CrossRefPubMed
31.
Zurück zum Zitat Cornford P et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol. 2016 Cornford P et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol. 2016
32.
Zurück zum Zitat Ohlmann CH, Gschwend J, Miller K. Drug therapy of hormone-sensitive metastatic prostate cancer: Consensus paper of the AKO/AUO. Urologe A. 2016;55:1164–72CrossRefPubMed Ohlmann CH, Gschwend J, Miller K. Drug therapy of hormone-sensitive metastatic prostate cancer: Consensus paper of the AKO/AUO. Urologe A. 2016;55:1164–72CrossRefPubMed
33.
Zurück zum Zitat James ND et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024): 1163–77CrossRefPubMedPubMedCentral James ND et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024): 1163–77CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Sweeney CJ. ECOG: CHAARTED-ChemoHormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer. Clin Adv Hematol Oncol. 2006;4:588–90PubMed Sweeney CJ. ECOG: CHAARTED-ChemoHormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer. Clin Adv Hematol Oncol. 2006;4:588–90PubMed
36.
Zurück zum Zitat Sooriakumaran P et al. A Multi-institutional Analysis of Perioperative Outcomes in 106 Men Who Underwent Radical Prostatectomy for Distant Metastatic Prostate Cancer at Presentation. Eur Urol. 2016;69:788–94CrossRefPubMed Sooriakumaran P et al. A Multi-institutional Analysis of Perioperative Outcomes in 106 Men Who Underwent Radical Prostatectomy for Distant Metastatic Prostate Cancer at Presentation. Eur Urol. 2016;69:788–94CrossRefPubMed
37.
Zurück zum Zitat Gratzke C, Engel J, Stief CG. Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry. Eur Urol. 2014;66:602–3CrossRefPubMed Gratzke C, Engel J, Stief CG. Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry. Eur Urol. 2014;66:602–3CrossRefPubMed
38.
Zurück zum Zitat Miller K et al. Metastatic castration-resistant prostate cancer: Clinical data, new treatment options and therapy monitoring. Urologe A. 2016;55:1206–12CrossRefPubMed Miller K et al. Metastatic castration-resistant prostate cancer: Clinical data, new treatment options and therapy monitoring. Urologe A. 2016;55:1206–12CrossRefPubMed
39.
Zurück zum Zitat Fendler WP et al. Radionuclide therapy and diagnostics in urology. Urologe A. 2015;54:1025–37CrossRefPubMed Fendler WP et al. Radionuclide therapy and diagnostics in urology. Urologe A. 2015;54:1025–37CrossRefPubMed
40.
Zurück zum Zitat Hoskin P et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014;15:1397–406CrossRefPubMed Hoskin P et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014;15:1397–406CrossRefPubMed
41.
Zurück zum Zitat Parker C et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23CrossRefPubMed Parker C et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23CrossRefPubMed
42.
Zurück zum Zitat Fendler WP et al. Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer. Oncotarget. 2016. Fendler WP et al. Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer. Oncotarget. 2016.
43.
Zurück zum Zitat Tagawa ST et al. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19:5182–91CrossRefPubMedPubMedCentral Tagawa ST et al. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19:5182–91CrossRefPubMedPubMedCentral
Metadaten
Titel
Update 2017
Das müssen Sie heute zum Prostatakarzinom wissen
verfasst von
Dr. med. Annika Herlemann
Dr. med. Alexander Kretschmer
Maria Apfelbeck
PD Dr. med. Stefan Tritschler
Dr. med. Wolfgang Fendler
Prof. Dr. med. Peter Bartenstein
Prof. Dr. med. Dr. h.c. Maximilian Reiser
Prof. Dr. med. Christian G. Stief
Prof. Dr. med. Christian Gratzke
Publikationsdatum
06.03.2017
Verlag
Springer Medizin
Erschienen in
MMW - Fortschritte der Medizin / Ausgabe 4/2017
Print ISSN: 1438-3276
Elektronische ISSN: 1613-3560
DOI
https://doi.org/10.1007/s15006-017-9037-3

Weitere Artikel der Ausgabe 4/2017

MMW - Fortschritte der Medizin 4/2017 Zur Ausgabe

FORTBILDUNG . SCHWERPUNKT

Das bringt den Darm in Schwung